Navigation Links
Moderate Aerobics May Ease Insomnia Symptoms
Date:6/12/2008

Brazilian study finds 36% reduction in time awake and a drop in anxiety levels

THURSDAY, June 12 (HealthDay News) -- A session of moderate aerobic exercise can help reduce anxiety and improve the quality of sleep for insomnia patients, according to a Brazilian study. Heavy aerobic or moderate strength exercises don't have the same effect.

Researchers at the Federal University of Sao Paulo divided 28 women and eight men with primary chronic insomnia into three exercise groups -- moderate aerobic, heavy aerobic, and moderate strength -- and one control group.

After the exercise session, those who did moderate aerobic exercise showed reductions in sleep onset latency (54 percent) and wake time (36 percent) and increases in total sleep time (21 percent) and sleep efficiency (18 percent). They also showed a 7 percent decrease in anxiety.

"These findings indicate that there is a way to diminish the symptoms of insomnia without using medication," study author Giselle S. Passos said in a prepared statement.

"This is the first study to look at the importance of using physical exercise to treat insomnia and may contribute to increased quality of life in people with one of the most important kind of sleep disorders around the world," Passos said.

The findings were presented Wednesday at the annual meeting of the Associated Professional Sleep Societies, in Baltimore.

More information

The American Academy of Family Physicians has more about insomnia.



-- Robert Preidt



SOURCE: American Academy of Sleep Medicine, news release, June 11, 2008


'/>"/>
Copyright©2008 ScoutNews,LLC.
All rights reserved

Page: 1

Related medicine news :

1. New Study Demonstrates Ramelteon Does Not Exacerbate Respiratory Depressant Effects in Patients With Moderate-to-Severe COPD
2. Moderate Exercise Cuts Risk of Metabolic Syndrome
3. Gene variant linked to moderated symptoms of beta-thalassemia
4. Moderate Aerobic Fitness Levels May Cut Stroke Risk
5. A Drug With Efficacy Superior to That of Memantine Would Earn up to a 50% Patient Share in the Moderate-to-Severe Alzheimers Disease Drug Market
6. Moderate alcohol consumption in middle age can lower cardiac risk
7. Ad in USA TODAY Touts Benefits of Moderate UV Exposure
8. FDA Approves Taclonex Scalp(R) - Once Daily Therapy for Treatment of Moderate to Severe Scalp Psoriasis
9. Drug Works Well for Moderate-to-Severe Psoriasis
10. IF You Had Survived a Brutal Rape at Gunpoint, Would You Teach Aerobics to Convicted Felons?
11. Aerobics Celebrates 40th Anniversary
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/19/2017)... ... 2017 , ... Bio-Optronics Inc. is proud to announce the ... to seamlessly integrate and streamline the way researchers prepare and conduct patient visits. ... and improving efficiency significantly for users – a first in the CTMS industry. ...
(Date:1/19/2017)... , ... January 19, 2017 , ... Students interested in ... Donation Awareness Scholarship competition., The winner will earn a $1,000 scholarship and have his ... begins Feb. 1, and the deadline is May 31, with the winner announced on ...
(Date:1/19/2017)... ... January 19, 2017 , ... Workrite Ergonomics announced this week ... Tranquility privacy panel system was designed to deliver the ideal blend of acoustic ... and provide the visual privacy required to maintain concentration levels and increase productivity. ...
(Date:1/19/2017)... ... ... Allegheny Health Network (AHN) officials today announced a bold new step to ... services in the greater Pittsburgh region. Starting January 23, patients who call AHN by ... same afternoon. , AHN is the first healthcare provider in the ...
(Date:1/19/2017)... , ... January 19, 2017 , ... ... protection and financial planning services to communities throughout eastern Georgia, is embarking on ... heart disease. , Heart disease kills more Americans every year than anything else, ...
Breaking Medicine News(10 mins):
(Date:1/19/2017)... 2017 Shire plc (LSE: SHP, ... Food and Drug Administration (FDA) has acknowledged receipt of ... (NDA) for SHP465, a long-acting, triple-bead, mixed amphetamine salts ... treatment for Attention-Deficit/Hyperactivity Disorder (ADHD). The FDA is expected ... 2017, the designated Prescription Drug User Fee Act (PDUFA) ...
(Date:1/19/2017)... 19, 2017 While various ... about reducing the FDA,s regulatory strictness as a ... medical drug industry, many of the leading biotech ... trials and development of advanced drug treatments and ... recent developments include:  Moleculin Biotech, Inc., (NASDAQ: ...
(Date:1/19/2017)... The Global Therapy Partnering Terms and Agreements ... deals and agreements entered into by the world,s leading ... Top deals by value - Deals listed by company ... The report provides understanding and access to the partnering ... healthcare companies. The report provides an analysis of ...
Breaking Medicine Technology: